EGFR and cancer: Impairment of the EGFR/Ras/Raf/MEK/ERK cascade by anti-EGFR, anti-Raf, or anti-MEK anti-cancer drugs could enhance type I IFN response, giving rise to inflammatory events in the skin and possibly also in the intestinal tract, the two most important targets of their adverse events [13].